{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:01:36Z","timestamp":1781326896390,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T00:00:00Z","timestamp":1531440000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00393-018-0507-5","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T08:08:18Z","timestamp":1531469298000},"page":"477-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Was der Rheumatologe vom Pneumologen lernen kann","What rheumatologists can learn from pneumologists"],"prefix":"10.1007","volume":"77","author":[{"given":"G.","family":"Leuschner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Neurohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,13]]},"reference":[{"key":"507_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-0032-1326009","volume":"67","author":"J Behr","year":"2013","unstructured":"Behr J, Gunther A, Ammenwerth W et\u00a0al (2013) German guideline for diagnosis and management of idiopathic pulmonary fibrosis. Pneumologie 67:81\u2013111","journal-title":"Pneumologie"},{"key":"507_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12890-017-0462-y","volume":"17","author":"J Behr","year":"2017","unstructured":"Behr J, Neuser P, Prasse A et al (2017) Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) \u2013 a\u00a0randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulm Med 17:122","journal-title":"BMC Pulm. Med."},{"key":"507_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378:498\u2013506","journal-title":"Lancet"},{"key":"507_CR4","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","volume":"73","author":"JG Coghlan","year":"2014","unstructured":"Coghlan JG, Denton CP, Grunig E et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73:1340\u20131349","journal-title":"Ann Rheum Dis"},{"key":"507_CR5","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","volume":"76","author":"JG Coghlan","year":"2017","unstructured":"Coghlan JG, Galie N, Barbera JA et al (2017) Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 76:1219\u20131227","journal-title":"Ann Rheum Dis"},{"key":"507_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ et\u00a0al (2016) Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 194:265\u2013275","journal-title":"Am J Respir Crit Care Med"},{"key":"507_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","volume":"193","author":"U Costabel","year":"2016","unstructured":"Costabel U, Inoue Y, Richeldi L et\u00a0al (2016) Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 193:178\u2013185","journal-title":"Am J Respir Crit Care Med"},{"key":"507_CR8","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.chest.2017.05.015","volume":"152","author":"TJ Doyle","year":"2017","unstructured":"Doyle TJ, Dellaripa PF (2017) Lung manifestations in the rheumatic diseases. Chest 152:1283\u20131295","journal-title":"Chest"},{"key":"507_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.12.012","author":"C Fernandez-Diaz","year":"2018","unstructured":"Fernandez-Diaz C, Loricera J, Castaneda S et al (2018) Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Semin Arthritis Rheum. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2017.12.012","journal-title":"Semin Arthritis Rheum"},{"key":"507_CR10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3899\/jrheum.121043","volume":"40","author":"A Fischer","year":"2013","unstructured":"Fischer A, Brown KK, Du Bois RM et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J\u00a0Rheumatol 40:640\u2013646","journal-title":"J Rheumatol"},{"key":"507_CR11","doi-asserted-by":"publisher","first-page":"1602493","DOI":"10.1183\/13993003.02493-2016","volume":"50","author":"S Gaine","year":"2017","unstructured":"Gaine S, Chin K, Coghlan G et al (2017) Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir\u00a0J 50:1602493. \n                    https:\/\/doi.org\/10.1183\/13993003.02493-2016","journal-title":"Eur Respir J"},{"key":"507_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie N, Humbert M, Vachiery JL et\u00a0al (2016) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart\u00a0J 37:67\u2013119","journal-title":"Eur Heart\u00a0J"},{"key":"507_CR13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NS Goh","year":"2008","unstructured":"Goh NS, Desai SR, Veeraraghavan S et\u00a0al (2008) Interstitial lung disease in systemic sclerosis: a\u00a0simple staging system. Am J Respir Crit Care Med 177:1248\u20131254","journal-title":"Am J Respir Crit Care Med"},{"key":"507_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00393-016-0196-x","volume":"75","author":"D Grund","year":"2016","unstructured":"Grund D, Siegert E (2016) Pulmonary fibrosis in rheumatic diseases. Z\u00a0Rheumatol 75:795\u2013808","journal-title":"Z Rheumatol"},{"key":"507_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1183\/09031936.00156312","volume":"42","author":"B Hervier","year":"2013","unstructured":"Hervier B, Meyer A, Dieval C et\u00a0al (2013) Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir\u00a0J 42:1271\u20131282","journal-title":"Eur Respir J"},{"key":"507_CR16","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1183\/09031936.00081512","volume":"42","author":"P Huppmann","year":"2013","unstructured":"Huppmann P, Sczepanski B, Boensch M et\u00a0al (2013) Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir\u00a0J 42:444\u2013453","journal-title":"Eur Respir J"},{"key":"507_CR17","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","volume":"53","author":"CA Kelly","year":"2014","unstructured":"Kelly CA, Saravanan V, Nisar M et al (2014) Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics \u2013 a large multicentre UK study. Rheumatology 53:1676\u20131682","journal-title":"Rheumatology"},{"key":"507_CR18","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr.","year":"2014","unstructured":"King TE Jr., Bradford WZ, Castro-Bernardini S et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N\u00a0Engl J Med 370:2083\u20132092","journal-title":"N Engl J Med"},{"key":"507_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fmed.2017.00176","volume":"4","author":"G Leuschner","year":"2017","unstructured":"Leuschner G, Behr J (2017) Acute exacerbation in interstitial lung disease. Front Med (Lausanne) 4:176","journal-title":"Front Med (Lausanne)"},{"key":"507_CR20","doi-asserted-by":"publisher","first-page":"33226","DOI":"10.1038\/srep33226","volume":"6","author":"T Li","year":"2016","unstructured":"Li T, Guo L, Chen Z et\u00a0al (2016) Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep 6:33226","journal-title":"Sci Rep"},{"key":"507_CR21","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","volume":"71","author":"FM Meier","year":"2012","unstructured":"Meier FM, Frommer KW, Dinser R et\u00a0al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355\u20131360","journal-title":"Ann Rheum Dis"},{"key":"507_CR22","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ et\u00a0al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:1760\u20131769","journal-title":"Lancet"},{"key":"507_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","volume":"183","author":"AL Olson","year":"2011","unstructured":"Olson AL, Swigris JJ, Sprunger DB et al (2011) Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 183:372\u2013378","journal-title":"Am J Respir Crit Care Med"},{"key":"507_CR24","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ et al (2011) An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788\u2013824","journal-title":"Am J Respir Crit Care Med"},{"key":"507_CR25","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, Du Bois RM, Raghu G et\u00a0al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N\u00a0Engl J Med 370:2071\u20132082","journal-title":"N Engl J Med"},{"key":"507_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.13-1474","volume":"145","author":"CJ Ryerson","year":"2014","unstructured":"Ryerson CJ, Vittinghoff E, Ley B et al (2014) Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 145:723\u2013728","journal-title":"Chest"},{"key":"507_CR27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1183\/13993003.00357-2015","volume":"47","author":"JJ Solomon","year":"2016","unstructured":"Solomon JJ, Chung JH, Cosgrove GP et al (2016) Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir\u00a0J 47:588\u2013596","journal-title":"Eur Respir J"},{"key":"507_CR28","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann Rheum Dis 66:940\u2013944","journal-title":"Ann Rheum Dis"},{"key":"507_CR29","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.rmed.2008.12.019","volume":"103","author":"T Suda","year":"2009","unstructured":"Suda T, Kaida Y, Nakamura Y et\u00a0al (2009) Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 103:846\u2013853","journal-title":"Respir Med"},{"key":"507_CR30","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ et\u00a0al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N\u00a0Engl J Med 354:2655\u20132666","journal-title":"N Engl J Med"},{"key":"507_CR31","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a\u00a0randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719","journal-title":"Lancet Respir Med"},{"key":"507_CR32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM et\u00a0al (2013) An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733\u2013748","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0507-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0507-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0507-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T19:03:30Z","timestamp":1562958210000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0507-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,13]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["507"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0507-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,13]]},"assertion":[{"value":"13 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Leuschner erhielt Reisekosten\u00fcbernahme f\u00fcr Konferenzen von Boehringer Ingelheim, Intermune und Novartis. C.\u00a0Neurohr ist als Referent t\u00e4tig und erh\u00e4lt Beraterhonorare von Actelion, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis und Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}